Genome-wide association studies to understand immune diseases
Genetic variants are alternative versions of the DNA sequence that can sometimes be associated with the risk of developing a disease, including autoimmune disorders. Determining the causality between genetic variants and autoimmunity is difficult, due to technical limitations of existing mapping strategies. Blagoje Soskic and collaborators summarise how Genome-wide association studies (GWAS) have contributed to investigating the impact of diverse genetic variants in several autoimmune diseases and discuss both current challenges and future research directions.
Autoimmune disorders – for example, lupus, rheumatoid arthritis, and ulcerative colitis, among others – arise when the immune system attacks bodily tissues and organs. Why the immune system turns against the body remain largely unknown, but host genetics is considered one of the risk factors for autoimmunity. Autoimmune diseases are often determined by variation in the DNA regions controlling function of many genes and are therefore defined as polygenic disorders. In rare cases, mutations in a single gene can also cause an autoimmune disease, which is accordingly called monogenic. GWAS can look at a whole genome of many people at the same time and have been used for the identification of specific DNA variants associated with autoimmune diseases. Furthermore, GWAS have been useful to determine the overall risk of developing a certain autoimmune disease or to respond to a certain drug.
Blagoje Soskic – Research Group Leader at the Human Technopole Genomics Research Centre – and colleagues from the University of Milano-Bicocca, Humanitas University and IRCCS Humanitas Research Hospital, and University of California, Davis, review techniques and approaches that, together with GWAS, allow fine mapping of human genetic variance as well as the identification of genes and cell types involved in immune disorders. The researchers discuss the contribution of exome- and whole-genome sequencing to identify rare variants, and the link between epigenetics and autoimmunity. Finally, Gerusi and Soskic et al. highlight the need for robust statistical and experimental approaches to understand the functions of newly identified genetic variants and their evolutionary history in immune diseases.
The review is published in the Journal of Autoimmunity.
Share:
You could also like:
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.
-
Human Technopole Foundation’s Supplier List online
The Human Technopole Foundation’s Supplier Register is now online.
-
HT Director Zerial Awarded Mercurio Prize for Excellence in Research
The Human Technopole Director, Marino Zerial, has been awarded the 2024 Mercurio Prize in the “Research and Development” category, in recognition of the excellence of his research in the field of cell biology. Zerial, renowned for his studies on the mechanisms of endocytosis and cellular transport, has made significant contributions to the understanding of cellular dynamics, with potential therapeutic applications for diseases such as liver conditions.
-
A new model system for cortical development in vitro
Researchers from Human Technopole, the Institute of Molecular Biotechnology and Bicocca University established a method for developing brain assembloids that allows reproducing salient aspects of the antero-posterior polarity of the human cerebral cortex in vitro and opens new possibilities for disease modelling. The study is published in Nature Methods.
-
The National Facility for Genomics with Clelia Peano
Meet Clelia Peano, Head of the National Facility for Genomics. The Facility offers cutting-edge services to develop robust experimental and analytical workflows to explore different genomic research areas, including DNA and RNA analysis, chromatin structure, and epigenetic mechanisms regulating transcription. The goal is to enhance genomic research in all its aspects, benefiting the entire Italian scientific community.